Welcome to LookChem.com Sign In|Join Free
  • or
(D-SER4)-GONADORELIN, also known as Gonadotropin-releasing hormone (GnRH), is a synthetic peptide that functions as an agonist at the gonadotropin-releasing hormone receptor. It serves as a crucial regulator in the reproductive system by controlling the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. These hormones subsequently stimulate the production of sex hormones like testosterone and estrogen, playing a vital role in the regulation of ovulation, spermatogenesis, and fertility.

103065-82-3

Post Buying Request

103065-82-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

103065-82-3 Usage

Uses

Used in Reproductive Medicine:
(D-SER4)-GONADORELIN is used as a medical treatment for conditions such as infertility, delayed puberty, and certain hormonal disorders. It aids in the regulation of hormone levels, thereby improving reproductive health and addressing the underlying issues.
Used in Cancer Management:
In the field of oncology, (D-SER4)-GONADORELIN is used for the management of hormone-dependent cancers like prostate and breast cancer. By acting on the hormonal regulation, it can help control the progression of these cancers, which often rely on hormonal stimulation for growth.
Used in Pharmaceutical Research:
Due to its synthetic nature, (D-SER4)-GONADORELIN offers potential advantages over natural gonadotropin-releasing hormone, such as increased stability and longer-lasting effects. This makes it a valuable compound for research and development in the pharmaceutical industry, where it can be used to create more effective and precise treatments for various conditions related to the reproductive and endocrine systems.

Check Digit Verification of cas no

The CAS Registry Mumber 103065-82-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,3,0,6 and 5 respectively; the second part has 2 digits, 8 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 103065-82:
(8*1)+(7*0)+(6*3)+(5*0)+(4*6)+(3*5)+(2*8)+(1*2)=83
83 % 10 = 3
So 103065-82-3 is a valid CAS Registry Number.

103065-82-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 10, 2017

Revision Date: Aug 10, 2017

1.Identification

1.1 GHS Product identifier

Product name 5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosylglycyl-L-leucyl-L-arginyl-L-prolylglycinamide

1.2 Other means of identification

Product number -
Other names (D-SER4)-LHRH

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:103065-82-3 SDS

103065-82-3Relevant academic research and scientific papers

IMPROVEMENTS IN SOLID PHASE PEPTIDE SYNTHESIS

-

Paragraph 0071-0076, (2017/08/01)

An improved method of deprotection in solid phase peptide synthesis is disclosed. In particular the deprotecting composition is added in high concentration and small volume to the mixture of the coupling solution, the growing peptide chain, and any excess activated acid from the preceding coupling cycle, and without any draining step between the coupling step of the previous cycle and the addition of the deprotection composition for the successive cycle. Thereafter, the ambient pressure in the vessel is reduced with a vacuum pull to remove the deprotecting composition without any draining step and without otherwise adversely affecting the remaining materials in the vessel or causing problems in subsequent steps in the SPPS cycle.

Solid-phase peptide synthesis in highly loaded conditions

Nakaie, Clovis R.,Oliveira, Eliandre,Vicente, Eduardo F.,Jubilut, Guita N.,Souza, Sinval E.G.,Marchetto, Reinaldo,Cilli, Eduardo M.

experimental part, p. 101 - 109 (2011/06/25)

The use of very highly substituted resins has been avoided for peptide synthesis due to the aggravation of chain-chain interactions within beads. To better evaluate this problem, a combined solvation-peptide synthesis approach was herein developed taking as models, several peptide-resins and with peptide contents values increasing up to near 85%. Influence of peptide sequence and loading to solvation characteristics of these compounds was observed. Moreover, chain-chain distance and chain concentration within the bead were also calculated in different loaded conditions. Of note, a severe shrinking of beads occurred during the α-amine deprotonation step only when in heavily loaded resins, thus suggesting the need for the modification of the solvent system at this step. Finally, the yields of different syntheses in low and heavily loaded conditions were comparable, thus indicating the feasibility of applying this latter "prohibitive" chemical synthesis protocol. We thought these results might be basically credited to the possibility, without the need of increasing molar excess of reactants, of carrying out the coupling reaction in higher concentration of reactants - near three to seven folds - favored by the use of smaller amount of resin. Additionally, the alteration in the solvent system at the α-amine deprotonation step might be also improving the peptide synthesis when in heavily loaded experimental protocol.

Characterization of the degradation products of luteinizing hormone releasing hormone

Motto,Hamburg,Graden,Shaw,Cotter

, p. 419 - 423 (2007/10/02)

The degradation products of luteinizing hormone releasing hormone [LH/RH; 1; gonadorelin releasing hormone (GnRH); 2] were determined in aqueous solution (pH 6.5) at 25, 37, 50, and 80 °C. The predominant route of degradation involved the cleavage of the 2 to the free acid form in peptides 4 and 10. Racemization of the serine and histidine residues to give peptides 2 and 3 was a second route of degradation.

Synthesis of Gonadoliberin, a Gonadotropin Releasing Hormone

Rzeszotarska, Barbara,Masiukiewicz, Elzbieta,Kmiecik-Chmura, Halina

, p. 791 - 798 (2007/10/02)

A simple laboratory synthesis of gonadoliberin was elaborated basing on classical solution methods and using minimal protection of the side-chain functions.In the final step a hexapeptide segment was condensed with the corresponding tetrapeptide and the obtained product was purified by a single step silica gel chromatography.The total efficiency of the whole synthesis was 15percent.

Synthetic decapeptide having the activity of the luteinizing hormone releasing hormone and method for manufacturing the same

-

, (2008/06/13)

A synthetic decapeptide, L-pglutamyl-L-histidyl-L-tryptophanyl-L-seryl-L-tyrosyl-glycyl-L-leucyl-L-arginyl-L-prolyl-glycinamide which has the hormonal activities of the luteinizing hormone releasing hormone (LRH) of the hypothalamus gland of mammals is produced by utilizing as the key starting materials, the amino acids, glutamic acid or pyroglutamic acid, histidine, tryptophan, serine, tyrosine, glycine, leucine, arginine, and proline. Synthesis of the decapeptide is accomplished by coupling, in appropriate combinations of appropriate protected forms of the amino acids, and finally deprotecting to yield the amide, L-pglutamyl-L-histidyl-L-tryptophanyl-L-seryl-L-tyrosyl-glycyl-L-leucyl-L-arginyl-L-prolyl-glycinamide.

Synthesis and biological activity of some analogs of the gonadotropin releasing hormone

Arnold,Flouret,Morgan,Rippel,White

, p. 314 - 319,315, 316 (2007/10/05)

Twenty one analogs of gonadotropin releasing hormone 2 (GnRH), were synthesized by the solid phase method. The derivatives were 3 (GnRH methyl ester), GnRH N methyl amide, GnRH free acid, 2 (Gn RH N terminal hexapeptide), and also [Ac Ala1], [Ac gly1], [D 1], [Pro1], [Arg2], [Tyr(Me)3], [Ser5], [des Gly6], [Sar6], [des Pro9], [des Gly10, Pro NH29], [des Gly10, Pro NHC2H59], [Tyr11], [Tyr(Me)35], [des His2, des Pro9], [des His2, Sar6], and [Sar6 des Tyr5] GnRH. All analogs were purified at both the protected and the deblocked stage. The final products were characterized by chemical and physical methods and assayed in vitro for both LH and FSH release using rat pituitaries. Those derivatives which showed less than 0.2% of the activity of GnRH itself were further tested for inhibition of gonadotropin release.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 103065-82-3